Adverse reactions to Zn1-24 ACTH therapy associated with specific cellular immunity
Glass, D.; Roffe, L.; Maini, R.N.; Wraith, D.G.; Nuki, G.
Clinical and Experimental Immunology 20(1): 55-63
1975
ISSN/ISBN: 0009-9104 PMID: 173487 Document Number: 90294
Lymphocyte transformation to 1-24ACTH, as assessed by the incorporation of tritiated thymidine, has been demonstrated to be associated with severe adverse reactions occurring in patients receiving a Zn-linked 1-24ACTH preparation (Tetra cosactrin depot, 'Synacthen'). Antibodies measured with an isotope-binding assay occurred commonly in all patients receiving therapy and did not correlate with adverse reactions. Lymphocyte transformation with the 1-24ACTH polypeptide, a part of the naturally occurring ACTH molecule, has not been previously recorded. The significance of antibodies and cell-mediated immunity to this polypeptide hormone is discussed.